Core Viewpoint - Changfeng Pharmaceutical (02652) has initiated the clinical validation phase for its self-developed bronchial valve lung volume reduction device, marking a significant step towards providing a minimally invasive treatment option for patients with emphysema and chronic obstructive pulmonary disease (COPD) [1] Group 1: Company Developments - The stock price of Changfeng Pharmaceutical increased by 2.74%, reaching HKD 29.2, with a trading volume of HKD 5.3645 million [1] - The first patient enrollment (FPI) for the clinical trial has been successfully completed, officially commencing the clinical validation phase [1] - The device aims to address unmet clinical needs in long-term management and quality of life improvement for emphysema patients, who often experience dynamic hyperinflation and activity limitations [1] Group 2: Clinical Research Details - The clinical study will focus on continuous enrollment, perioperative safety monitoring, and multi-dimensional assessments of imaging and lung function [1] - Key indicators will include safety related to the device and procedure, technical success rates, and changes in critical clinical outcomes such as FEV1, RV, 6MWD, and SGRQ [1] - The research data will create an auditable evidence chain for future registration strategies and commercialization decisions [1]
长风药业午前涨近3% 公司治疗肺气肿领域的微创介入器械完成首例入组